



Patients achieving any of the five defined treatment initiation targets after 4 months: Dupilumab + TCS: 86%; Placebo + TCS: 57%



Patients achieving any of the five defined treatment initiation targets after 6 months: Dupilumab + TCS: 80%; Placebo + TCS: 45%



Patients achieving any of the 5 defined treatment initiation targets after 1 year: Dupilumab + TCS: 79%; Placebo + TCS: 33%

Fig. S1. (A) Percentage of patients achieving Eczema Area and Severity Index (EASI)-50, ≥3-point improvement in Peak Pruritus numerical rating scale (NRS), ≥4-point improvement in Dermatology Life Quality Index (DLQI), ≥4-point improvement in Patient-Oriented Eczema Measure (POEM), or ≥1-point improvement in Patient's Global Assessment of Disease Status (PGADS), at week 16. (B) Percentage of patients achieving EASI ≤7, Peak Pruritus NRS score ≤4, DLQI ≤5, POEM ≤7, or PGAD of "good, very good or excellent", at 6 months. (C) 1 year. q2w: every 2 weeks.